• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: President and COO Tardio Jason bought $9,884 worth of shares (12,512 units at $0.79) (SEC Form 4)

    6/20/25 5:16:19 PM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMUX alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tardio Jason

    (Last) (First) (Middle)
    1200 AVENUE OF THE AMERICAS, SUITE 200

    (Street)
    NEW YORK NY 10036

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    IMMUNIC, INC. [ IMUX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and COO
    3. Date of Earliest Transaction (Month/Day/Year)
    06/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    06/09/2025
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/05/2025 P 12,512 A $0.79 12,512 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $0.7729 06/05/2025 A 598,500 (1) 06/05/2035 Common Stock 598,500 $0.00 598,500 D
    Explanation of Responses:
    1. 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.
    Remarks:
    This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Peron on June 9, 2025 to correct an administrative error that incorrectly reported the number of stock options granted.
    /s/ Jason Tardio 06/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMUX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMUX

    DatePrice TargetRatingAnalyst
    3/25/2025Outperform
    William Blair
    11/25/2024$10.00Buy
    H.C. Wainwright
    9/9/2024$5.00Outperform
    Leerink Partners
    8/27/2024$6.00Buy
    B. Riley Securities
    10/21/2022$5.00Outperform → Mkt Perform
    SVB Leerink
    9/19/2022$26.00Buy
    H.C. Wainwright
    9/7/2021$40.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMUX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: President and COO Tardio Jason bought $9,884 worth of shares (12,512 units at $0.79) (SEC Form 4)

      4/A - IMMUNIC, INC. (0001280776) (Issuer)

      6/20/25 5:16:19 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Chief Financial Officer Whaley Glenn

      4/A - IMMUNIC, INC. (0001280776) (Issuer)

      6/20/25 5:16:01 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CEO and Director Vitt Daniel bought $11,550 worth of shares (15,000 units at $0.77), increasing direct ownership by 107% to 29,000 units (SEC Form 4)

      4/A - IMMUNIC, INC. (0001280776) (Issuer)

      6/20/25 5:15:45 PM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMUX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Immunic

      William Blair initiated coverage of Immunic with a rating of Outperform

      3/25/25 8:27:26 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Immunic with a new price target

      H.C. Wainwright initiated coverage of Immunic with a rating of Buy and set a new price target of $10.00

      11/25/24 7:45:37 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners resumed coverage on Immunic with a new price target

      Leerink Partners resumed coverage of Immunic with a rating of Outperform and set a new price target of $5.00

      9/9/24 7:37:13 AM ET
      $IMUX
      Biotechnology: Pharmaceutical Preparations
      Health Care